Johnson & Johnson (J&J)

The new software incorporates AI-powered nodule segmentation, which is designed to generate more precise boundaries around lung nodules during pre-procedural planning.

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

The investment forms part of the company’s broader plan to spend US$55 billion on expanding its domestic manufacturing footprint through 2029.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

The initiative integrates Johnson & Johnson’s Polyphonic™ open digital ecosystem with DOH Abu Dhabi and leading technology partners, including Amazon Web Services (AWS) and NVIDIA.

Varipulse Pro will receive prominent visibility at the European Heart Rhythm Association (EHRA) annual meeting, where J&J plans to conduct live procedure demonstrations and offer practical training sessions for healthcare professionals.

Psoriasis is a chronic autoimmune disorder in which skin cells multiply excessively, creating thick, itchy, scaly patches that affect more than 8 million Americans.

The new facility will generate approximately 500 permanent biomanufacturing positions once operational.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.